Drug intelligence / Profile preview

gam-mers-vac

Development stage: Phase 2
Lead developer: Gamaleya Center
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Gam-MERS-Vac (BVRS-GamVac) is a heterologous recombinant adenovirus-based vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology to protect against Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Similar in design to the Sputnik V COVID-19 vaccine, it utilizes two different adenoviral vectors—Ad5 and Ad26—both carrying the gene for the MERS-CoV spike (S) protein. The vaccine is administered in a prime-boost regimen to induce both humoral and cell-mediated immune responses. It has undergone Phase 1 and Phase 2 clinical trials in Russia, demonstrating safety and immunogenicity in healthy adults.

Other names: BVRS + GamVacMERS-GamVacGamaleya MERS vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on gam-mers-vac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gam-mers-vac.

Explore the full profile